Ocular hypotensive efficacy and safety of travoprost 0.004% in inadequately controlled primary open-angle glaucoma or ocular hypertension: Short-term, multicenter, prospective study

Mirella Blini, Gemma Caterina Maria Rossi, Giuseppe Trabucchi, Maria R. Curatola, Alessandro David, Rosella Radaelli, Giancarlo Merlo, Roberto Ratiglia

Research output: Contribution to journalArticlepeer-review

Abstract

Objective: To evaluate the intraocular pressure (IOP) lowering efficacy and safety of travoprost 0.004% in patients with open-angle glaucoma or ocular hypertension, poorly controlled with or intolerance to beta-blockers. To record the short-term effect on diastolic ocular perfusion pressure (DOPP). Research design and methods: One hundred and three patients with open-angle glaucoma or ocular hypertension were treated with travoprost 0.004% once daily for 90 days in an open-label, non-controlled study. Efficacy and safety were assessed at baseline, after 45 and 90 days. Clinical registry number IT0301. Main outcome measures: The primary outcome measure, IOP, was recorded at 10 am, 12 pm, and 4 pm at each visit. DOPP was evaluated at 10 am, at baseline and visit 3. Safety measures included adverse events, biomicroscopy, visual acuity, heart rate, and blood pressure. Results: Mean IOP was reduced from 22.2±1.7 mmHg to 16.5±2.1 after 45 days (p

Original languageEnglish
Pages (from-to)57-63
Number of pages7
JournalCurrent Medical Research and Opinion
Volume25
Issue number1
DOIs
Publication statusPublished - Jan 2009

Keywords

  • DOPP (diastolic ocular perfusion pressure)
  • Glaucoma
  • Intraocular pressure
  • IOP fluctuation
  • Ocular hypertension
  • Prostaglandin analogue
  • Travoprost

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Ocular hypotensive efficacy and safety of travoprost 0.004% in inadequately controlled primary open-angle glaucoma or ocular hypertension: Short-term, multicenter, prospective study'. Together they form a unique fingerprint.

Cite this